Brethine: profile and news






Everyday Asthma Control Secrets  Mar 5, 2006
Brethine, Proventil, Tornalate are examples of inhaled bronchodilators. They are rescue medicines and can be used on a regular basis for fast relief. ... - DailyIndia.com,

Florence firm near getting 2 drugs  Jul 14, 2005
The division sold also makes Brethine, an inhalant for people with asthma; Roxicodone, which has the same chemical composition as the widely abused painkiller ... - Cincinnati Enquirer

Lannett gets FDA OK for generic Brethine  Mar 29, 2005
...reported Tuesday that the Food and Drug Administration approved its application to market a version of Novartis Pharmaceuticals' Brethine tablets. ... - BusinessWeek

Lannett's generic Brethine gets FDA OK  Mar 31, 2005
...from the FDA for its abbreviated new drug application for terbutaline sulfate tablets, the generic equivalent of Novartis and aaiPharma's Brethine, used for ... - Pharmaceutical Business Review

Even Skilled Physicians Make Mistakes  Apr 25, 2005
...labor. I gave an order for Brethine 0.4mg over the phone. I then wrote my discharge orders for the lady with the miscarriage. I ... - Wall Street Journal (subscription)

AaiPharma to restate earnings; stock to be delisted  Apr 15, 2005
...also will include an additional $15.3 million of impairment charges related to intangible assets associated with its Darvon/Darvocet and Brethine product lines ... - Raleigh Triangle Business Journal

aaiPharma Common Stock to be Delisted from NASDAQ on April 18 ...  Apr 15, 2005
...as well as an additional $15.3 million of impairment charges related to intangible assets associated with its Darvon(R)/Darvocet(R) and Brethine(R) product ... - Business Wire

FDA approves Lannett respiratory drug  Mar 29, 2005
Terbutaline Sulfate is the generic equivalent of Brethine tablets, which are marketed by Novartis Pharmaceuticals and aaiPharma Inc. ... - Philadelphia Business Journal

Lannett Receives FDA Approval for Terbutaline; Company to Launch ...  Mar 29, 2005
...years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema, and is the generic equivalent of Brethine(R) Tablets ... - Business Wire,

Lannett gets FDA OK for generic Brethine  Mar 29, 2005
...reported Tuesday that the Food and Drug Administration approved its application to market a version of Novartis Pharmaceuticals' Brethine tablets. ... - BusinessWeek

Lannett's generic Brethine gets FDA OK  Mar 31, 2005
...from the FDA for its abbreviated new drug application for terbutaline sulfate tablets, the generic equivalent of Novartis and aaiPharma's Brethine, used for ... - Pharmaceutical Business Review

FDA approves Lannett respiratory drug  Mar 29, 2005
Terbutaline Sulfate is the generic equivalent of Brethine tablets, which are marketed by Novartis Pharmaceuticals and aaiPharma Inc. ... - Philadelphia Business Journal,

Lannett Receives FDA Approval for Terbutaline; Company to Launch ...  Mar 29, 2005
...years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema, and is the generic equivalent of Brethine(R) Tablets ... - Business Wire (press release),


Other information


Indication
For the prevention of and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema; For the management of preterm labor

Pharmacology
Terbutaline is a relatively selective beta2-adrenergic bronchodilator. Terbutaline is indicated for the relief of bronchospasm associated with chronic obstructive pulmonary disease. The pharmacologic effects of beta adrenergic agonist drugs, including Terbutaline, are at least in part attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

Mechanism Of Action
The pharmacologic effects of Terbutaline are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic AMP. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

Drug Category
Adrenergic beta-Agonists; Tocolytic Agents; Bronchodilator Agents; Sympathomimetic; ATC:R03AC03; ATC:R03CC03

Brand Names/Synonyms
Brethaire; Brethine; Brican; Bricanyl; Bricar; Bricaril; Bricyn; CHEMBANK743; KWD 2019; T2528; Terbutalin; Terbutalina [Dcit]; Terbutaline; Terbutaline Sulfate; Terbutalino [Inn-Spanish]; Terbutalinum [Inn-Latin]

Dosage Forms
METERED-DOSE (AEROSOL); POWDER; Tablets; IV Injection; Subcutaneous Injection

Absorption
Not Available

Interactions
Drug Interactions: The concomitant use of Terbutaline with other sympathomimetic agents is not recommended, since the combined effect on the cardiovascular system may be deleterious to the patient. Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: Terbutaline should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline on the vascular system may be potentiated. Beta-Blockers: Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as Terbutaline, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. Diuretics: The ECG changes and/or hypokalemia that may result from the administration of nonpotassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics.

Chemical IUPAC Name
5-(1-hydroxy-2-tert-butylamino-ethyl)benzene-1,3-diol

Chemical Formula
C12H19NO3

Half Life
5.5-5.9 hours

Drug Type
Approved Drug

# Accession No
APRD00589

CAS Registry Number
23031-25-6

Home | About | Cancers | Treatment | Medications
Copyright onconews.org 2005.
All Rights Reserved.
Google
 
Web onconews.org